In search of p53 target genes for the therapeutic manipulation of cancer

Current Opinion in Drug Discovery and Development

Volumn 9, Issue 2, 2006, Pages 176-183

  Liu, Suxing ^a   Seidel Dugan, Cynthia ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioinformatics; Cancer genomics; Cancer therapy; Drug target; Human genome; Microarray; p53; Target identification; Target validation; Transcription factor

Indexed keywords

ABT 737; AEG 35156; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARQ 850; AT 9283; B 717; CGP 84700; DOXORUBICIN; GOSSYPOL; GX 15 070; ISIS 23722; JNJ 27291199; LIC 101; LY 2181308; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CS 1008; MONOCLONAL ANTIBODY HGS ETR2; MONOCLONAL ANTIBODY HGS TR2J; MP 235; OBLIMERSEN; PHA 739358; PRO 1762; PROTEIN BAX; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN P53; R 763; RO 4435385; SNS 314; SPC 2996; SPC 3042; SURDEX; SYNTHETIC PEPTIDE; TRANSCRIPTION FACTOR; TRANSCRIPTOME; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 528; VX 680; X LINKED INHIBITOR OF APOPTOSIS; YM 155;

APOPTOSIS; BIOINFORMATICS; CANCER; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DNA MICROARRAY; DRUG RESPONSE; DRUG TARGETING; GENE MAPPING; GENE TARGETING; GENE THERAPY; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME PROJECT; NONHUMAN; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; VALIDATION PROCESS;

ANIMALS; DRUG DESIGN; GENE TARGETING; GENE THERAPY; GENES, P53; HUMANS; NEOPLASMS;

EID: 33645019758     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature (2000) 408(6810):307-310.
2. 1 arrest and apoptosis. Cancer Res (1994) 54(5):1169-1174.
3. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DO, Green DR: PUMA couples the nuclear and cytoplasmic proapoptotic function of p63. Science (2005) 309(5741):1732-1735.
4. 2 phase. J Biol Chem (2000) 275(30):22627-22630.
5. Wu GS, Burns TF, McDonald ER 3rd, Meng RD, Kao G, Muschel R, Yen T, el-Deiry WS: Induction of the TRAIL receptor KILLER/DR5 in p63-dependent apoptosis but not growth arrest. Oncogene (1999) 18(47):6411-6418.
6. Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E et al: Wild-type human p53 and a temperature-sensitive mutant induce Fas/Apo-1 expression. Mol Cell Biol (1995) 15(6):3032-3040.
7. Robles AI, Bemmels NA, Foraker AB, Harris CC: Apaf-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res (2001) 61(18):6660-6664.
8. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p63-induced apoptosis. Nature (1997) 389(6648):300-305. Describes a SAGE study leading to a model for p53-induced apoptosis through transcriptional induction of redox-related genes.
9. Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier P, Greene JR, Liu S: Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene (2003) 22(23):3645-3654. Describes an integrated approach, combining gene expression with global p53 DNA binding site analysis to monitor a p53 global transcription program during the process of apoptosis and cell-cycle progression.
10. Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P, Greene JR, Wang Y, Pickett CB, Liu S: Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem (2001) 276(47):43604-43610. Provides the first publication of global p53 DNA binding site analysis integrated with gene expression and chromatin immunoprecipitation analyses.
11. Liu S, Mirza A, Wang L: Generation of p63 target database via integration of microarray and global p63 DNA-binding site analysis. Methods Mol Biol (2004) 281:33-54. Describes the methodology of global p53 DNA binding site analysis and integration with microarray data.
12. Miled C, Pontoglio M, Garbay S, Yaniv M, Weitzman JB: A genomic map of p53 binding sites identifies novel p63 targets involved in an apoptotic network. Cancer Res (2005) 65(12):5096-5104. Describes a global p53 DNA binding site analysis using a p53 PWM, in an approach different from that described in reference [10••].
13. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, Piccolboni A, Sementchenko V, Cheng J, Williams AJ, Wheeler R et al: Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell (2004) 116(4):499-509. Describes ChIP-on-chip experiments on genome tiling arrays and their application to p53 binding sequences.
14. Weinberg RL, Veprintsev DB, Bycroft M, Fersht AR: Comparative binding of p63 to its promoter and DNA recognition elements. J Mol Biol (2005) 348(3):589-596.
15. Tomso DJ, Inga A, Menendez D, Pittman GS, Campbell MR, Storici F, Bell DA, Resnick MA: Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci USA (2005) 102(18):6431-6436.
16. Wu G, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, Basso A, McClanahan T, Luo L, Kirschmeier P, Gustafson E et al: Integrate genomics revealed RA13 is a cell growth-promoting gene and a novel p53 transcriptional target J Biol Chem (2005) 280(13):12935-12943. Describes the application of integrative genomics to identify potential oncogenes in the p53 pathway for antitumor drug target discovery.
17. Sachse C, Echeverri CJ: Oncology studies using sIRNA libraries: The dawn of RNAI-based genomics. Oncogene (2004) 23(51):8384-8391.
18. Sachse C, Krausz E, Kronke A, Hannus M, Walsh A, Grabner A, Ovcharenko D, Dorris D, Trudel C, Sonnichsen B, Echeverri CJ: High-throughput RNA interference strategies for target discovery and validation by using synthetic short interfering RNAs: Functional genomics investigations of biological pathways. Methods Enzymol (2005) 392:242-277.
19. MacKeigan JP, Murphy LO, Blenis J: Sensitized RNAI screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol (2005) 7(6):591-600.
20. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, Kerkhoven RM, Madiredjo M, Nijkamp W, Weigelt B, Agami R et al: A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 428(6981):431-437. Describes the fascinating application of an RNAi library to identify novel components in the p53 pathway.
21. Liu S, Bishop WR, Dasmahapatra B, Wang Y: Pharmacogenomics of the p53 tumor suppressor and its role in cancer chemoresistance. Drug Dev Res (2004) 62(3):254-272. Provides a review of the pharmacogenomics of p53 tumor suppressor and its role in cancer chemoresistance.
22. Middelburg R, de Haas RR, Dekker H, Kerkhoven RM, Pohlmann PR, Fuentes-Alburo A, Mohar A, Pinedo HM, Lankelma J: Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res (2005) 11(5):1863-1869.
23. Nakano K, Vousden KH: PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell (2001) 7(3):683-694.
24. Waf1/Cip1 pathway by 5-aza-2′-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol (2005) 26(4):863-871.
25. Clarke PA, Pestell KE, Di Stefano F, Workman P, Walton MI: Characterization of molecular events following cisplatin treatment of two curable ovarian cancer models: Contrasting role for p53 induction and apoptosis in vivo. Br J Cancer (2004) 91(8):1614-1623.
26. Bouchal J, Baumforth KR, Svachova M, Murray PG, von Angerer E, Kolar Z: Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol (2005) 57(1):83-92.
27. Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M: Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem (1996) 60(1):23-32.
28. Chan SL, Yu VC: Proteins of the Bcl-2 family in apoptosis signalling: From mechanistic insights to therapeutic opportunities. Clin Exp Pharmacol Physiol (2004) 31(3):119-128.
29. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 435(7042):677-681.
30. Lo HW, Day CP, Hung MC: Cancer-specific gene therapy. Adv Genet (2005) 54:235-255.
31. Fleischer A, Ghadiri A, Dessauge F, Duhamel M, Rebollo MP, Alvarez-Franco F, Rebollo A: Modulating apoptosis as a target for effective therapy. Mol Immunol (2005) 43(8):1065-1079.
32. Kelley SK, Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol (2004) 4(4):333-339.
33. Georgakis GV, Li Y, Humphreys R, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A: Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol (2005) 130(4):501-510.
34. Li F, Ambrosin G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altier OC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature (1998) 396(6711):580-584.
35. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL et al: Human survivin is negatively regulated by wild-type p53 and participates in pS3-dependent apoptotic pathway. Oncogene (2002) 21(17):2613-2622.
36. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PT: Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 13(9):3064-3077.
37. Yan X, Cao L, Li Q, Wu Y, Zhang H, Saiyin H, Liu X, Zhang X, Shi Q, Yu L: Aurora C is directly associated with survivin and required for cytokinesis. Genes Cells (2005) 10(6):617-626.
38. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czemiak BA, Sen S: Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet (2004) 36(1):55-62.
39. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N et al: In vivo activation of the p53 pathway by small-molecule antagonists of Mdm2. Science (2004) 303(5859):844-848.
40. Vassilev LT: p53 Activation by small molecules: Application in oncology. J Med Chem (2005) 48(14):4419-4499.
41. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT: Activation of p53 by Mdm2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res (2005) 65(5):1918-1924.
42. Csermely P, Agoston V, Pongor S: The efficiency of multi-target drugs: The network approach might help drug design. Trends Pharmacol Sci (2005) 26(4):178-182.